NCT02587598 Study of INCB053914 in Subjects With Advanced Malignancies Status TERMINATED Phase PHASE1/PHASE2
NCT02577406 An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation Status COMPLETED Phase PHASE3
NCT02553941 Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Status COMPLETED Phase PHASE1
NCT02543879 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Status COMPLETED Phase PHASE1
NCT02530463 Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02508870 A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Status COMPLETED Phase PHASE1
NCT02472691 Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT Status COMPLETED Phase PHASE2
NCT02458235 Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation Status COMPLETED Phase PHASE2
NCT02450877 A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. Status COMPLETED Phase PHASE2
NCT02447666 Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) Status COMPLETED Phase PHASE2
NCT02421939 A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation Status COMPLETED Phase PHASE3
NCT02399917 Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Status TERMINATED Phase PHASE2
NCT02397720 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Status COMPLETED Phase PHASE2
NCT02367456 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients Status COMPLETED Phase PHASE1
NCT02343939 Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) Status TERMINATED Phase PHASE1/PHASE2
NCT02341495 Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65 Status TERMINATED Phase PHASE2
NCT02265510 An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Status TERMINATED Phase PHASE1/PHASE2
NCT02260440 A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2
NCT02203773 Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) Status TERMINATED Phase PHASE1
NCT02201329 Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Status COMPLETED Phase PHASE1